

# Contents

---

<b>Foreword</b>	<b>xiii</b>
<b>1. Drug Discovery and Development: An Overview of Modern Methods and Principles</b>	<b>1</b>
Drug Discovery and Development from 20,000 Feet	8
Target Selection: The First Step Forward	11
Hit Identification: Finding a Starting Point	15
Identify a Clinical Candidate: Juggling the Properties	21
Questions	26
References	27
<b>2. The Drug Discovery Process: From Ancient Times to the Present Day</b>	<b>35</b>
The Age of Botanicals: Preindustrial Drug Discovery	36
Paul Ehrlich: The Father of Modern Drug Discovery	39
Milestones in Drug Discovery	41
Milestones in Animal Models: Breeding a Better Model	42
The Wistar Rat	42
Immunocompromised Mice	43
Transgenic Animal Models	44
Knockout Animal Models	45
Milestones in Molecular Science	47
X-ray Crystallography	48
Molecular Modeling and Computational Chemistry	50
High Throughput Technology: Chemical Synthesis and Screening Science	53
Milestones in Biotechnology	59
Recombinant DNA and Transfection Technology	60
Polymerase Chain Reaction (PCR) Technology	62
Monoclonal Antibody and Hybridoma Technology	64
The Rise of Biologics and Macromolecular Therapeutics	66
Societal and Governmental Impacts	67
The Pure Food and Drug Act of 1906	68
The Elixir of Sulfanilamide Disaster of 1937	69
The Thalidomide Story	71



Regulatory Milestones	73
Durham–Humphrey Amendment of 1951	74
Kefauver–Harris Amendment of 1962	74
Hatch–Waxman Act of 1984	75
Biologics Price Competition and Innovation Act of 2009	77
Future Developments in Drug Discovery	78
Questions	78
References	79
 3. Classical Targets in Drug Discovery	 87
Protein Structure	89
Enzymes	95
Inhibition of Enzymes	101
G-Protein-Coupled Receptors (GPCRs)	105
G-Protein-Dependent Signaling Pathways	109
cAMP Signaling	110
IP <sub>3</sub> Signaling	111
Modulating GPCR Activity	112
Ion Channels	116
Gating Mechanisms	120
Ligand-Gated Channels	120
Voltage-Gated Channels	123
Other Gating Mechanisms	126
Membrane Transport Proteins (Transporters)	126
Emerging Targets	134
Questions	135
References	136
 4. <i>In vitro</i> Screening Systems	 143
The Language of Screening: Basic Terms	144
Concentration Response Curves and IC <sub>50</sub> s	145
Dissociation Constants (K <sub>d</sub> ) and Inhibition Constants (K <sub>i</sub> )	146
Efficacy versus Binding: EC <sub>50</sub> s	148
Agonist, Partial Agonist, Antagonist, Allosteric Modulators, and Inverse Agonists	149
Agonists and Partial Agonists	150
Antagonists	151
Basal Activity and Inverse Agonists	151
Allosteric Modulation	151
Receptor Reserve	152
Streptavidin and Biotin	153
Biochemical versus Cellular Assays	154
Assay Systems and Methods of Detection	156
Radioligand Assay Systems	157
Scintillation Proximity Assay (SPA)	159
Enzyme-Linked Immunosorbent Assay (ELISA)	162
Fluorescence-Based Assay Systems	164



Fluorescence Polarization (FP)	165
Fluorescence Resonance Energy Transfer (FRET)	168
Time-Resolved Fluorescence Resonance Energy Transfer (TRFRET)	172
Amplified Luminescent Proximity Homogeneous Assay (AlphaScreen™)	175
Fluorescent Detection of Calcium Flux	177
Reporter Gene Assays	180
Chloramphenicol Acetyltransferase (CAT)	181
$\beta$ -Lactamase Reporter Assays	182
Luciferase Reporter Assays	183
Kinetic Fluorescent Measurement Systems	184
Label-Free Assay Systems	185
Cellular Dielectric Spectroscopy	186
Optical Biosensors	187
Surface Plasmon Resonance Technology	190
Electrophysiological Patch Clamp	191
General Consideration for All Screening Methods	194
Questions	196
References	197
 5. Medicinal Chemistry	 203
Structure–Activity Relationships and Structure–Property Relationships	204
The Role of Chirality	209
Push and Pull in Structure–Activity Relationships	212
Quantitative Structure–Activity Relationships	213
The Pharmacophore	218
Developing an SAR Data Set	220
The Structure–Activity Relationship Cycle	231
Bioisosterism	232
Structure–Activity Relationship, Selectivity and Physicochemical Properties	236
“Druglike” Guidelines	237
Questions	239
References	240
 6. <i>In vitro</i> ADME and <i>In vivo</i> Pharmacokinetics	 245
Absorption	249
Solubility	250
Permeability	254
Distribution	262
Permeability	264
Transporters	266
Plasma Protein Binding	268
Elimination Pathways	270
Metabolism	271
Excretion	283
<i>In vitro</i> ADME Screening Methods	287



<i>In vivo</i> Pharmacokinetics	289
Volume of Distribution	291
Clearance	293
Half-life	294
Bioavailability	296
Species Selection	299
Questions	300
References	301
<b>7. Animal Models of Disease States</b>	<b>307</b>
Sources of Animal Models	309
Validity of Animal Models	312
Species Selection	313
Number of Animals	314
Exemplary Animal Models by Disease Category	314
Animal Models in Neuroscience	315
The Forced Swimming Test: A Model of Depression	315
The Elevated Plus Maze: A Measure of Anxiety	315
The Novel Object Recognition Test: A Model of Memory and Cognition	316
Contextual Fear Conditioning Model: A Model of Contextual Learning	317
The Morris Water Maze: A Model of Spatial Learning and Memory	318
Animal Models of Neurodegeneration	320
The SOD1-G93A Mouse of Amyotrophic Lateral Sclerosis	320
The MPTP Model of Parkinson's Disease	321
Animal Models of Cardiovascular Disease	323
Models of Hypertension	323
Models of Hyperlipidemia and High Cholesterol	325
Models of Atrial Fibrillation	327
Models of Heart Failure	329
Animal Models of Infectious Disease	332
Murine Thigh Infection Model	332
Murine Model of Systemic Infection	333
The Mouse Model of Influenza Virus Infection	334
Limitations of Animal Models of Infection	335
Animal Models of Oncology	335
Mouse Xenograft Tumor Model	336
Mouse Allograft Tumor Model	337
Genetically Engineered Mouse Models of Cancer	338
Questions	339
References	340
<b>8. Safety and Toxicology</b>	<b>345</b>
Sources of Toxicity	347
Acute versus Chronic Toxicity	353
Cytotoxicity	354



Carcinogenicity, Genotoxicity, and Mutagenicity	356
Drug–Drug Interactions	360
Cardiovascular Safety and Toxicology Studies	362
Central Nervous System Safety and Toxicology Studies	369
Immune System Mediated Safety Issues	371
Teratogenicity	373
<i>In vivo</i> Toxicity and Safety Studies	375
Questions	376
References	377
 9. Basics of Clinical Trials	 383
Before the Clinic	386
Drug Supply	386
Delivery Methods	389
Formulation	391
Investigational New Drug Application	395
Phase I Clinical Trials	397
Phase II Clinical Trials	399
Phase III Clinical Trials	402
Phase IV Clinical Trials	407
Adaptive Clinical Trial Design	409
Questions	410
References	410
 10. Translational Medicine and Biomarkers	 415
Definition of a Biomarker and Their Classification	418
Characteristics and Impact of Biomarkers	421
Biomarkers versus Surrogate End Points	423
Imaging Technologies	424
The Practical Application of Biomarkers	432
DPP-IV Inhibitors (Januvia®)	432
Physiological Measurements as Biomarkers: Orexin Antagonists	434
FDG PET Imaging Agent	436
The Neurokinin 1 (NK <sub>1</sub> ) Receptor, Depression, and PET Imaging: The Aprepitant Story	438
Questions	440
References	440
 11. Organizational Considerations and Trends in the Pharmaceutical Industry	 447
Organizational Structures of Pharmaceutical Companies	448
Business Divisions Interactions	448
The Discovery Project Team Evolutionary Cycle	449
The Business Climate	452
Mergers and Acquisitions	453
Contract Research Organizations	457



Academic Drug Discovery	460
Funding Issues	465
Questions	467
References	468
<b>12. Intellectual Property and Patents in Drug Discovery</b>	<b>471</b>
Patentable Subject Matter	473
Inherent Properties and Patentability	477
Novelty and the Prior Art	479
Obviousness and the Prior Art	480
Inventorship	483
Assignment and Ownership	485
Classification of Patents and Patent Applications	486
Impact of Overlapping Patents	487
Patent Applications and Their Contents	488
Contents of a Patent Application	492
Questions	497
References	497
<b>13. Case Studies in Drug Discovery</b>	<b>499</b>
Tamiflu: From Mechanism of Action to Marketed Drug	499
Histone Deacetylase Inhibitors: Physicochemical Optimization via Structural Change	504
HIV Protease Inhibitors: Chemically Complex Miracle Drugs	506
Nitrofurantoin: A Surprisingly Successful Drug	511
Seldane® (Terfenadine) versus Allegra® (Fexofenadine): Metabolism Matters: Safety	513
Claritin® (Loratadine) versus Clarinex® (Desloratadine): Metabolism Matters: Pharmacokinetics	516
MPTP: Parkinson's Disease in a Bottle	517
Bupropion and Methylphenidate: Improving Performance via Formulation Changes	521
Selective Inhibition of Cyclooxygenase-2: The Impact of an Inadequate Written Description	524
Questions	526
References	526
<b>Appendix 1</b>	<b>531</b>
<b>Answers to Questions in Textbook by Chapter</b>	<b>539</b>
<b>Subject Index</b>	<b>565</b>
<b>Drug Index</b>	<b>579</b>

Companion site for this book can be accessed at  
<http://booksite.elsevier.com/9780124115088>